Alpha Tau Medical Ltd. (DRTS)

NASDAQ: DRTS · IEX Real-Time Price · USD
3.67
-0.02 (-0.54%)
At close: Feb 7, 2023, 4:00 PM
3.74
+0.07 (1.91%)
After-hours: Feb 7, 2023, 7:23 PM EST
-0.54%
Market Cap 253.27M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 69.01M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,285
Open 3.62
Previous Close 3.69
Day's Range 3.60 - 3.74
52-Week Range 3.00 - 20.65
Beta n/a
Analysts Buy
Price Target 17.60 (+379.56%)
Earnings Date Mar 27, 2023

About DRTS

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 83
Stock Exchange NASDAQ
Ticker Symbol DRTS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for DRTS stock is "Buy." The 12-month stock price forecast is $17.6, which is an increase of 379.56% from the latest price.

Price Target
$17.6
(379.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023

JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, a...

2 months ago - GlobeNewsWire

Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

JERUSALEM, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™...

2 months ago - GlobeNewsWire

Alpha Tau to Present at Upcoming November Investor Conferences

JERUSALEM, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...

3 months ago - GlobeNewsWire

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology

- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes Hospital in Cambridge -

3 months ago - GlobeNewsWire

OurCrowd Launches $200 Million Global Health Equity Fund in collaboration with the WHO Foundation at the Clinton Global Initiative

NEW YORK--(BUSINESS WIRE)--OurCrowd, a leading global venture firm, announced today the launch of a Global Health Equity Fund (GHEF) in collaboration with the WHO Foundation. The news was shared at th...

Other symbols: BYND
5 months ago - Business Wire

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Al

– Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, the official journal of the American Soc...

5 months ago - GlobeNewsWire

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Pete...

5 months ago - GlobeNewsWire

Alpha Tau Medical to Participate in Upcoming September Investor Conferences

JERUSALEM, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the Compan...

5 months ago - GlobeNewsWire

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

- Received FDA Conditional Investigational Device Exemption (IDE) , whose conditions have since been satisfied, to initiate a pivotal trial of Alpha DaRT ™ in recurrent cutaneous squamous cell carcino...

5 months ago - GlobeNewsWire

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and M...

6 months ago - GlobeNewsWire

Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials

JERUSALEM, July 05, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced...

7 months ago - GlobeNewsWire

Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™

JERUSALEM , June 22, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the firs...

8 months ago - PRNewsWire

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

JERUSALEM , June 8, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, an...

8 months ago - PRNewsWire

Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors

JERUSALEM , June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaR...

8 months ago - PRNewsWire

Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update

-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gross proceeds- -Targeted start of U.S. multi-center pivotal trial in skin canc...

9 months ago - PRNewsWire

First Alpha DaRT Patients Treated in France as Part of Alpha DaRT™ Multicenter Skin Cancer Trial

JERUSALEM , May 23, 2022 /PRNewswire/ -- Alpha Tau Medical (Nasdaq: DRTS) (Nasdaq: DRTSW) , the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that the first p...

9 months ago - PRNewsWire

Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update

JERUSALEM, March 28, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha Da...

11 months ago - PRNewsWire

12 Stocks Halted On A Circuit Breaker This Week

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and br...

11 months ago - Benzinga

Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination

JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd.

1 year ago - PRNewsWire

Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer

JERUSALEM, Jan. 20, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has signed a sponsore...

1 year ago - PRNewsWire

Healthcare Capital Corp Announces Special Meeting Date for Proposed Business Combination with Alpha Tau Medical Ltd.

NEW YORK, New York and JERUSALEM, Israel, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp (NASDAQ: HCCC, HCCCW, and HCCCU) (“HCCC”) today announced that on January 12, 2022, the U.S. Securit...

1 year ago - GlobeNewsWire

Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer

JERUSALEM, Jan. 3, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by H...

1 year ago - PRNewsWire

Alpha Tau Announces Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)

JERUSALEM, Nov. 3, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has enrolled its first ...

1 year ago - PRNewsWire

Alpha Tau Announces Completion of Enrollment in First US Clinical Trial of Alpha DaRT™ and Achievement of First Primary Objective

JERUSALEM, Oct. 25, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that its US pilot trial for sk...

1 year ago - PRNewsWire

Alpha Tau and Healthcare Capital Corp. to Combine and Create A Publicly Traded Company Focused on Transforming the Treatment of Solid Tumors Through the Precision Delivery of Alpha Radiation

- Alpha Tau's proprietary Alpha DaRT™ is designed to deliver uniquely potent alpha radiation to destroy solid tumors with localized precision, sparing surrounding healthy tissue, thereby maintaining c...

1 year ago - PRNewsWire